MedTrace Logo

Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome

NCT06271538 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-12

No results posted yet for this study

Summary

The objective of this randomized, double-blind, placebo-controlled study is to evaluate the effectiveness of Skal Pro in alleviating symptoms, enhancing stool consistency, improving quality of life, and addressing psychological distress in individuals diagnosed with irritable bowel syndrome (IBS), as compared to those who receive no intervention.

Conditions

  • Irritable Bowel Syndrome
  • Gastrointestinal Diseases
  • Colonic Diseases, Functional
  • Intestinal Disease
  • Digestive System Disease
  • Pathologic Processes
  • Colonic Disease
  • Disease

Interventions

COMBINATION_PRODUCT

Skal Pro

One sachet Skal Pro per day containing Lactobacillus plantarum 299v 1x10\^10 CFU and GOS

OTHER

Placebo

One sachet per day identical in shape, size, colour, packaging and taste to the Skal Pro sachet

Sponsors & Collaborators

  • EP Plus Group Sdn Bhd

    lead INDUSTRY

Principal Investigators

  • Yeong Yeh Lee, MD, PhD · Hospital Universiti Sains Malaysia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-17
Primary Completion
2026-03-31
Completion
2026-06-30

Countries

  • Malaysia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06271538 on ClinicalTrials.gov